Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ESR1 | P03372 | 6/20 | 0.72 |
| ▸ | ESR2 | Q92731 | 6/20 | 0.72 |
| ▸ | ABHD6 | Q9BV23 | 5/20 | 0.68 |
| ▸ | PKM | P14618 | 1/20 | 0.51 |
| ▸ | HDAC6 | Q9UBN7 | 2/20 | 0.45 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.45 |
| ▸ | NPC1 | O15118 | 2/20 | 0.44 |
| ▸ | RAB9A | P51151 | 2/20 | 0.44 |
| ▸ | HSD17B3 | P37058 | 1/20 | 0.44 |
| ▸ | AKR1C3 | P42330 | 1/20 | 0.43 |
| ▸ | CCR2 | P41597 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30411956 | 1.00 | ESR1 (0.72) | ESR1ESR2ABHD6PKMHDAC6 | |
| SCHEMBL419896 | 0.94 | ESR2 (0.72) | ESR1ESR2ABHD6PKMHDAC6 | |
| SCHEMBL1787936 | 0.91 | ABHD6 (0.60) | ESR1ESR2ABHD6PKMHDAC6 | |
| SCHEMBL25200187 | 0.88 | ABHD6 (0.65) | ESR1ESR2ABHD6HDAC6HDAC8 | |
| SCHEMBL30575082 | 0.84 | ABHD6 (0.60) | ESR1ESR2ABHD6HDAC6HDAC8 | |
| SCHEMBL4183920 | 0.84 | ESR1 (0.74) | ESR1ESR2ABHD6PKMNPC1 | |
| SCHEMBL8266789 | 0.82 | ESR1 (0.72) | ESR1ESR2ABHD6PKMHDAC6 | |
| SCHEMBL13259386 | 0.82 | ESR1 (0.72) | ESR1ESR2ABHD6PKMHDAC6 | |
| SCHEMBL2616863 | 0.82 | ESR1 (0.72) | ESR1ESR2ABHD6PKMHDAC6 | |
| SCHEMBL1641841 | 0.82 | ESR1 (0.72) | ESR1ESR2ABHD6PKMHDAC6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 110 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250144094-A1 | THIOPHENE ULK1/2 INHIBITORS AND THEIR USE THEREOF | ERASCA, INC. | 2025-05-08 | — | — | US | disclosed |
| EP-4433059-A1 | THIOPHENE ULK1/2 INHIBITORS AND THEIR USE THEREOF | Erasca, Inc. (US) | 2024-09-25 | — | — | EP | disclosed |
| WO-2023215494-A1 | THIOPHENE ULK1/2 INHIBITORS AND THEIR USE THEREOF | ERASCA, INC. (US) | 2023-11-09 | — | — | WO | disclosed |
| WO-2023215494-A1 | THIOPHENE ULK1/2 INHIBITORS AND THEIR USE THEREOF | ERASCA, INC. (US) | 2023-11-09 | — | — | WO | disclosed |
| WO-2023087027-A1 | THIOPHENE ULK1/2 INHIBITORS AND THEIR USE THEREOF | ERASCA, INC. (US) | 2023-05-19 | — | — | WO | disclosed |
| WO-2023087027-A1 | THIOPHENE ULK1/2 INHIBITORS AND THEIR USE THEREOF | ERASCA, INC. (US) | 2023-05-19 | — | — | WO | disclosed |
| US-11084824-B2 | Pyrazolopyrimidine derivatives, preparation method thereof, and pharmaceutical composition for use in preventing or treating cancer, autoimmune disease and brain disease containing the same as an active ingredient | KOREA RESEARCH INSTITUTE OF CHEMICAL TECHNOLOGY (KR) | 2021-08-10 | — | — | US | disclosed |
| US-11084824-B2 | Pyrazolopyrimidine derivatives, preparation method thereof, and pharmaceutical composition for use in preventing or treating cancer, autoimmune disease and brain disease containing the same as an active ingredient | KOREA RESEARCH INSTITUTE OF CHEMICAL TECHNOLOGY (KR) | 2021-08-10 | — | — | US | disclosed |
| EP-3190113-B1 | PYRROLOPYRIMIDINE COMPOUNDS USED AS TLR7 AGONIST | CHIA TAI TIANQING PHARMACEUTICAL GROUP CO LTD (CN) | 2021-05-19 | — | — | EP | disclosed |
| EP-3097101-B1 | ISOQUINOLINE DERIVATIVES AS MGAT2 INHIBITORS | MERCK SHARP & DOHME (US) | 2020-12-23 | — | — | EP | disclosed |
| EP-0922035-B1 | TETRAHYDROISOQUINOLINE DERIVATIVES AND THEIR PHARMACEUTICAL USE | SMITHKLINE BEECHAM PLC (GB) | 2001-02-07 | — | — | EP | disclosed |
| US-6143762-A | DRUGS AS DOPAMINE ANTAGONIST PSYCHOLOGICAL DISORDERS | SMITHKLINE BEECHAM, PLC (GB) | 2000-11-07 | — | — | US | disclosed |
| EP-0983245-A1 | SUBSTITUTED TETRAHYDROISOQUINOLINE DERIVATIVES AS MODULATORS OF DOPAMINE D3 RECEPTORS | SMITHKLINE BEECHAM PLC (GB) | 2000-03-08 | — | — | EP | disclosed |
| EP-0983244-A1 | TETRAHYDROISOQUINOLINE DERIVATIVES AS MODULATORS OF DOPAMINE D3 RECEPTORS | SMITHKLINE BEECHAM PLC (GB) | 2000-03-08 | — | — | EP | disclosed |
| EP-0981516-A1 | SUBSTITUTED TETRAHYDROISOQUINOLINE DERIVATIVES AS MODULATORS OF DOPAMINE D?3 RECEPTORS | SMITHKLINE BEECHAM PLC (GB) | 2000-03-01 | — | — | EP | disclosed |
| EP-0922035-A1 | TETRAHYDROISOQUINOLINE DERIVATIVES AND THEIR PHARMACEUTICAL USE | SMITHKLINE BEECHAM PLC (GB) | 1999-06-16 | — | — | EP | disclosed |
| WO-1998051671-A1 | SUBSTITUTED TETRAHYDROISOQUINOLINE DERIVATIVES AS MODULATORS OF DOPAMINE D3 RECEPTORS | SMITHKLINE BEECHAM PLC (GB) | 1998-11-19 | — | — | WO | disclosed |
| WO-1998050364-A1 | TETRAHYDROISOQUINOLINE DERIVATIVES AS MODULATORS OF DOPAMINE D3 RECEPTORS | SMITHKLINE BEECHAM PLC (GB) | 1998-11-12 | — | — | WO | disclosed |
| WO-1998049145-A1 | SUBSTITUTED TETRAHYDROISOQUINOLINE DERIVATIVES AS MODULATORS OF DOPAMINE D3 RECEPTORS | SMITHKLINE BEECHAM PLC (GB) | 1998-11-05 | — | — | WO | disclosed |
| WO-1998006699-A1 | TETRAHYDROISOQUINOLINE DERIVATIVES AND THEIR PHARMACEUTICAL USE | SMITHKLINE BEECHAM PLC (GB) | 1998-02-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250144094-A1 | THIOPHENE ULK1/2 INHIBITORS AND THEIR USE THEREOF | ULK1, ULK2, ULK3 | ESR1 3000/4885ESR2 2354/4885ABHD6 4000/4885 |
| US-11084824-B2 | Pyrazolopyrimidine derivatives, preparation method thereof, and pharmaceutical composition for use in preventing or treating cancer, autoimmune disease and brain disease containing the same as an active ingredient | BTK, SYK, LCK | ESR1 4753/4885ESR2 4806/4885ABHD6 2337/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.